JP2015528295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528295A5 JP2015528295A5 JP2015530089A JP2015530089A JP2015528295A5 JP 2015528295 A5 JP2015528295 A5 JP 2015528295A5 JP 2015530089 A JP2015530089 A JP 2015530089A JP 2015530089 A JP2015530089 A JP 2015530089A JP 2015528295 A5 JP2015528295 A5 JP 2015528295A5
- Authority
- JP
- Japan
- Prior art keywords
- ntrk1
- gene fusion
- mprip
- mprip gene
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 230000004927 fusion Effects 0.000 claims description 55
- 238000003556 assay Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 239000000523 sample Substances 0.000 claims description 20
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 18
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 17
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 15
- 208000037841 lung tumor Diseases 0.000 claims description 13
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 238000009104 chemotherapy regimen Methods 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 229940043355 kinase inhibitor Drugs 0.000 claims description 11
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims description 9
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 9
- 101150111783 NTRK1 gene Proteins 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 101150003655 Mprip gene Proteins 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 4
- 230000009286 beneficial effect Effects 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 claims 2
- WVXNSAVVKYZVOE-UHFFFAOYSA-N DCC-2036 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C4C=CC=NC4=CC=3)=CC=2)=C1 WVXNSAVVKYZVOE-UHFFFAOYSA-N 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 2
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical group O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 2
- 229960005061 crizotinib Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229950003970 larotrectinib Drugs 0.000 claims 2
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 claims 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229940126496 utatrectinib Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101001028827 Homo sapiens Myosin phosphatase Rho-interacting protein Proteins 0.000 claims 1
- 102100037183 Myosin phosphatase Rho-interacting protein Human genes 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 230000009969 flowable effect Effects 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940044683 chemotherapy drug Drugs 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696002P | 2012-08-31 | 2012-08-31 | |
| US61/696,002 | 2012-08-31 | ||
| US201361827514P | 2013-05-24 | 2013-05-24 | |
| US61/827,514 | 2013-05-24 | ||
| PCT/US2013/057495 WO2014036387A2 (en) | 2012-08-31 | 2013-08-30 | Methods for diagnosis and treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528295A JP2015528295A (ja) | 2015-09-28 |
| JP2015528295A5 true JP2015528295A5 (enExample) | 2017-09-07 |
| JP6223451B2 JP6223451B2 (ja) | 2017-11-01 |
Family
ID=50184648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530089A Expired - Fee Related JP6223451B2 (ja) | 2012-08-31 | 2013-08-30 | がんの診断及び治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150218652A1 (enExample) |
| EP (1) | EP2890815B1 (enExample) |
| JP (1) | JP6223451B2 (enExample) |
| CA (1) | CA2882759C (enExample) |
| WO (1) | WO2014036387A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| PT3106463T (pt) | 2008-10-22 | 2018-05-18 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| HK1214831A1 (zh) | 2012-11-05 | 2016-08-05 | Foundation Medicine, Inc. | 新型融合分子及其应用 |
| AU2013337277B2 (en) * | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
| US10980804B2 (en) | 2013-01-18 | 2021-04-20 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US20170114415A1 (en) * | 2014-05-30 | 2017-04-27 | The Regents Of The University Of Colorado, A Body Corporate | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy |
| EP3218380B1 (en) | 2014-11-16 | 2021-03-17 | Array Biopharma, Inc. | Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| BR112018003588A2 (pt) * | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| RU2018122089A (ru) | 2015-11-19 | 2019-12-25 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| IL304018A (en) | 2016-04-04 | 2023-08-01 | Loxo Oncology Inc | Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide |
| ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) * | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| EA202091763A1 (ru) | 2018-01-31 | 2020-12-14 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия для лечения мастоцитоза |
| BR112021002145A2 (pt) * | 2018-08-07 | 2021-12-14 | In3Bio Ltd | Métodos e composições para inibição da via egf/egfr em combinação com inibidores da quinase de linfoma anaplásico |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| CN109988836B (zh) * | 2019-03-18 | 2022-06-07 | 厦门艾德生物技术研究中心有限公司 | 一种检测ntrk融合的fish探针组及其应用 |
| JP7818502B2 (ja) | 2019-08-12 | 2026-02-20 | デシフェラ・ファーマシューティカルズ，エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| SI4084778T1 (sl) | 2019-12-30 | 2024-01-31 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitorja amorfne kinaze in načini njihove uporabe |
| EP4114967A4 (en) * | 2020-02-28 | 2025-01-29 | Advanced Cell Diagnostics, Inc. | METHODS FOR DETECTING NTRK GENE FUSION USING RNA IN SITU HYBRIDIZATION |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122655B2 (en) * | 2002-11-15 | 2006-10-17 | New England Medical Center Hospital, Inc. | Compositions involving M-RIP, and related methods for screening for anti-hypertensive agents, and uses thereof |
| EP3266867A1 (en) * | 2006-04-14 | 2018-01-10 | Cell Signaling Technology, Inc. | Gene defects and mutant alk kinase in human solid tumors |
| US20120082978A1 (en) * | 2006-09-15 | 2012-04-05 | Linda Pilarski | Cell Analysis On Microfluidic Chips |
| EP2806054A1 (en) * | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| CA2762108A1 (en) * | 2009-05-15 | 2010-11-18 | Insight Genetics, Inc. | Methods and compositions relating to fusions of alk for diagnosing and treating cancer |
| WO2011060328A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2013059740A1 (en) * | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| AU2013337277B2 (en) * | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
-
2013
- 2013-08-30 US US14/423,867 patent/US20150218652A1/en not_active Abandoned
- 2013-08-30 JP JP2015530089A patent/JP6223451B2/ja not_active Expired - Fee Related
- 2013-08-30 WO PCT/US2013/057495 patent/WO2014036387A2/en not_active Ceased
- 2013-08-30 EP EP13832208.6A patent/EP2890815B1/en not_active Not-in-force
- 2013-08-30 CA CA2882759A patent/CA2882759C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528295A5 (enExample) | ||
| CA2882759C (en) | Detection of the ntrk1-mprip gene fusion for cancer diagnosis | |
| US20170114415A1 (en) | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy | |
| JP2010259438A5 (enExample) | ||
| JP5586607B2 (ja) | ２０個の遺伝子パネルを用いて潰瘍性大腸炎及び関連疾患を評価し治療するためのマーカー及び方法 | |
| JP2014533949A5 (enExample) | ||
| CN107022637B (zh) | 一种与重度抑郁症相关的基因标志物 | |
| KR101604178B1 (ko) | 약물에 의한 간 손상의 예측 및 진단을 위한 바이오마커 | |
| CN110129442A (zh) | 甲状腺癌的分子诊治标志物 | |
| KR20220039065A (ko) | 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커 | |
| CN116694764A (zh) | 一种增强人卵巢癌顺铂耐药性的piRNA标志物及其在检测和治疗中的应用 | |
| CN107630085B (zh) | 分子标志物在男性骨质疏松中的应用 | |
| CN108410978A (zh) | 重度抑郁症相关基因及其在诊断中的应用 | |
| KR101670135B1 (ko) | 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
| US10895574B2 (en) | Left-right gene expression signature for triple negative breast cancer | |
| CN108034707B (zh) | Spag7基因在制备老年痴呆诊断制剂中的应用 | |
| KR102731352B1 (ko) | 위암의 예후 예측 방법 | |
| KR101644682B1 (ko) | 전사체학과 단백질체학을 이용한 약물에 의한 간 손상의 예측 및 진단을 위한 바이오마커 | |
| CN113403382B (zh) | Ube2f在诊治股骨头坏死中的应用 | |
| KR20160043419A (ko) | 간암 바이오마커로서의 ＥＲＲγ 및 이의 용도 | |
| KR102343240B1 (ko) | 대장암 환자에서 세툭시맙에 대한 내성 예측용 바이오마커 조성물 | |
| WO2007053659A2 (en) | Method of screening for hepatocellular carcinoma | |
| CN115058512A (zh) | 铁死亡相关基因在鉴定缺血性脑卒中的应用 | |
| KR20150081632A (ko) | 약물에 의한 간 손상 유형을 조기에 진단하기 위한 정보를 제공하는 방법 | |
| KR101583397B1 (ko) | 인플루엔자 바이러스 a 감염 여부 판별용 키트 |